Polo-like kinase 1 promotes sepsis-induced myocardial dysfunction

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Sepsis Research

Background:

• Sepsis-induced myocardial dysfunction (SIMD) is a primary cause of mortality in sepsis patients.
• The molecular mechanisms driving SIMD remain incompletely understood.
• Identifying key regulators of SIMD is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of Polo-like kinase 1 (Plk-1) in the pathogenesis of SIMD.
• To determine if Plk-1 is a potential therapeutic target for mitigating SIMD.

Main Methods:

• Assessed Plk-1 expression in lipopolysaccharide (LPS)-induced mouse heart and neonatal rat cardiomyocyte (NRCM) models of sepsis.
• Utilized Plk-1 heterozygous knockout mice and the Plk-1 inhibitor BI 6727 to evaluate the effects of Plk-1 inhibition.
• Examined myocardial injury, inflammation, cardiac function, and survival rates in response to Plk-1 inhibition.
• Investigated the downstream signaling pathways affected by Plk-1, specifically the NF-κB pathway via IKKα.

Main Results:

• Plk-1 expression was significantly upregulated in LPS-treated hearts and NRCMs.
• Inhibition of Plk-1, through genetic deletion or pharmacological means, attenuated LPS-induced myocardial injury, inflammation, and cardiac dysfunction.
• Plk-1 inhibition improved the survival rate of LPS-treated mice.
• Plk-1 was identified as a kinase for inhibitor of kappa B kinase alpha (IKKα), and its inhibition suppressed NF-κB pathway activation.

Conclusions:

• Augmented Plk-1 expression is a critical factor in the development of SIMD.
• Plk-1 represents a druggable target for the treatment of sepsis-induced myocardial dysfunction.
• Targeting Plk-1 may offer a novel therapeutic strategy to improve outcomes in sepsis patients.